Emulating Trials and Quantifying Bias: The Convergence of Health Technology Assessment Agency Real-World Evidence Guidance
Value in Health · 2024
DOI: 10.1016/j.jval.2023.11.010 ↗Kurz gefasst
Leserbrief in der Zeitschrift Value in Health, 2024. Verfasst von Simon Chen und 3 weiteren Autor:innen. Beteiligte Einrichtung: Health Analytics, Lane Clark & Peacock LLP, London, England, UK. Hauptthemen laut MEDLINE: Technology Assessment, Biomedical, Research Design. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 11 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- Health Analytics, Lane Clark & Peacock LLP, London, England, UK.
- Health Analytics, Lane Clark & Peacock LLP, London, England, UK; Centre for Pharmaceutical Medicine Research, King's College London, England, UK. Electronic address: sreeram.ramagopalan@lcp.uk.com.
Zitieren
APA
Chen, S., Tikhonovsky, N., Dhanji, N., & Ramagopalan, S. (2024). Emulating Trials and Quantifying Bias: The Convergence of Health Technology Assessment Agency Real-World Evidence Guidance. Value in Health. https://doi.org/10.1016/j.jval.2023.11.010
Vancouver
Chen S, Tikhonovsky N, Dhanji N, Ramagopalan S. Emulating Trials and Quantifying Bias: The Convergence of Health Technology Assessment Agency Real-World Evidence Guidance. Value in Health. 2024. doi:10.1016/j.jval.2023.11.010
BibTeX
@article{Chen2024,
author = {Chen, Simon and Tikhonovsky, Natalie and Dhanji, Nishit and Ramagopalan, Sreeram},
title = {Emulating Trials and Quantifying Bias: The Convergence of Health Technology Assessment Agency Real-World Evidence Guidance},
journal = {Value in Health},
year = {2024},
doi = {10.1016/j.jval.2023.11.010}
}
EUVIMED